Strong on its subscribers' health data and its founder, with more of its own factories and labs than most assume
Read more
The pressure is on margins: its fastest-growing drug is not its own, so Hims does not set the price.
Proprietary data flywheel · Strong. Every consultation, test and treatment adds to a health record a newcomer cannot rebuild overnight. Unproven so far: Hims has never said how many people buy a second product.
Regulation & licences · Neutral. Weight-loss rules have been more threat than shield, but making its own drugs under licence turns that risk into something it controls. Treatments that need a video visit with a doctor and regular blood tests, like testosterone, shut out small telehealth brands.
Physical assets & network · Strong. A drug-making campus of over 300,000 square feet in Ohio, drug compounding in California and its own diagnostics lab: not the asset-light platform it is often taken for.
Trust & brand · Neutral. Well known with consumers, but after the weight-loss drug dispute, trust takes time to rebuild, and the FTC's main charge is about privacy: health information shared with advertising platforms.
Owner-operator · Strong. Co-founder Andrew Dudum is still CEO and keeps the high-vote shares, so other owners have little say, a trade-off many investors see as a serious risk. His bets are large, with no track record at this scale.
Leadership
Last reviewed 29 Oct 2026
Andrew Dudum
Co-founder, CEO and chairman
10 years at the helm
Owns7.1%
Votes87.7%
Founder and control · Strong. 175 votes a share: about 88% of all votes.
Skin in the game · Neutral. Owns about 7%. Sold about $200 million in 2024–25, bought none.
Track record · Neutral. Opened category after category, but made 'a significant mistake' in weight loss.
Pay and alignment · Strong. Over 90% of his pay is stock, tied to 2027 targets.
Bench and succession · Weak. Strong new hires, but control rests with one man.
Kentucky's pharmacy board gave no exemption to the 6 peptides eased by HHS on 28 Oct, and told pharmacies to stop shipping in at once. A national launch of BPC-157 and TB-500 now looks like a state-by-state patchwork. The American Medical Association called on HHS to withdraw the policy, which…
Hers UK launched Care+ at £39 a month with a home metabolic blood test, taking the US model abroad. STAT News and Medical Daily stress that compounded peptides have no FDA approval and no human randomised trials, as peptides go mainstream. UK Care+ is optional, while US Care+ is mandatory, and…
Peptides+ launched on 18 Nov, ahead of plan, bundled with Care+ lab testing that moves the testing-data loop forward. None of the 5 products is FDA-approved, and the legal basis is a 'temporary' enforcement discretion of 28 Oct. Three executives sold about $570,000 under 10b5-1 plans set in May…
Noom's new OpenRx brand fully overlaps two HIMS Peptides+ products, NAD+ and sermorelin, and went live earlier. Noom also launched a screenless wristband, copying the HIMS platform path of testing, peptides and wearables. HIMS can stand out only through its own US factory, user data and…
The FTC suit grew from two states to seven, with state consumer-protection claims added, tilting settlement leverage towards plaintiffs. Peptides+ launches at the end of November, but the chief financial officer says peptide revenue will be immaterial this year. Branded weight-loss drugs have cut…
Revenue rose 49%, but from higher spend per customer and acquisitions, not user growth. Subscribers fell by about 100,000 from Q2, hitting the premise behind the moat. Gross margin was 57% against 74% a year earlier, and full-year adjusted EBITDA guidance was cut.